A shining light for the biotechnology industry, for Kendall Square, and for patients with rare diseases has passed away. Henri Termeer founded and led Genzyme for close to 30 years, greatly influencing the rise of biotech and bringing a patient-centric approach to the business.
The funding, led by former Genzyme CEO Henri Termeer, funds the development of an immunomodulator that could be used for multiple sclerosis, type 1 diabetes, psoriasis and other autoimmune disease.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.